Severe purulent-septic diseases (sepsis, meningitis, peritonitis, septic endocarditis); infectious-inflammatory respiratory disease (pneumonia, pleural empyema, lung abscess); infections of the kidneys and urinary tract; suppurative complications in the postoperative period; infected burns; tuberculosis of the lungs and other organs tuberculous lesions caused by microorganisms resistant to antituberculous drugs I and II series and sensitive to kanamycin.

Treatment of infections caused by susceptible to cefuroxime by microorganisms or therapy to determine the infectious agent.
Infectious diseases of the respiratory tract: acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess, postoperative infections of the chest; infectious diseases of the nose and throat: sinusitis, tonsillitis, pharyngitis; infectious diseases of the urinary tract: acute and chronic pyelonephritis, cystitis, asymptomatic bacteriuria; infectious diseases of soft tissues: cellulites, erysipeloid, wound infection; infectious diseases of joints and bones: osteomyelitis, septic arthritis; infections in obstetrics and gynecology: an infectious-inflammatory diseases of the pelvic organs; gonorrhoea, especially in those cases when penicillin is contraindicated; other infectious diseases, including septicemia and meningitis. Prevention of infectious complications after operations on the thorax and abdomen, operations on the pelvic organs, vascular, cardiovascular and orthopedic operations. In most cases, monotherapy drug Kimacef is an effective, but if necessary, the drug can be used in combination with aminoglycoside antibiotics, or metronidazole (oral, rectal suppositories or injectable).In the case of existing or anticipated mixed aerobic and anaerobic infections (e.g., peritonitis, aspiration pneumonia, lung abscess, pelvic and brain) and the high incidence of such infections (e.g., in operations on the colon and gynecological surgery) acceptable is the drug of Kimacef in combination with metronidazole. In the treatment of pneumonia and exacerbation of chronic bronchitis drug Kimacef can be administered prior to oral application of the cefuroxime axetil when needed.

As part of complex treatment of post-traumatic, intra- and postoperative oedemas of any localization, i.e. severe cerebral and spinal oedemas, including those with intracranial hemorrhages, increased intracranial pressure and dropsical swelling; liquor-venous disturbances in patients with chronic ischemia of the brain and vegetative-vascular dystonia; soft tissue oedemas involving musculoskeletal system accompanied with local blood circulation disorders and pain syndrome; oedematous and pain syndromes in the spine, body, and extremities; severe venous circulation disorders of the low extremities in patients with acute thrombophlebitis accompanied with swelling inflammation syndrome.

Infectious inflammatory diseases due to laevomycetin-susceptible microorganisms: typhoid fever, paratyphoid fever, shigellosis, salmonellosis, brucellosis, tularemia, ricketsiosis (including spotted fever, trachoma).

Laevomycetin is indicated for typhoid fever, paratyphoid fever, generalized forms of salmonellosis, dysentery, brucellosis, tularemia, meningitis, spotted fever and other ricketsioses, trachoma. Infectious processes due to laevomycetin-susceptible pathogens when other chemotherapeutic preparations are ineffective or their administration is not feasible.

Benign peptic ulcer and duodenal ulcer, including those associated with the use of NSAIDs; gastroesophageal reflux disease; syndrome Zollinger-Ellison; for eradication of Helicobacter pylori (in combination with antibiotics).